105 completed, 35 unknown, 15 terminated, 13 recruiting. 86 Phase 2, 41 Phase 1, 39 Phase 3, 19 Phase 4, 17 Not applicable.
Follow Tretinoin: new trials by email Literature Review of Tretinoin trials Research Report on Tretinoin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance All-trans retinoic acid, Tislelizumab - EGFR-TKI-resistant Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 24 | 2026-10-01 | 2026-09-25 |
| Oral Tranexamic Acid Plus Triple Combination vs Triple Combination Alone in Melasma Oral tranexamic acid + triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin), Triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin) alone - Melasma, Melasma (Facial Melasma) | Phase 4 | Not yet recruiting | Combined Military Hospital Abbottabad | 128 | 2026-07-15 | 2026-07-28 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-20 |
| ATRA for Management of Primary ITP all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 192 | 2026-05-30 | 2026-05-19 |
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma all-trans retinoic acid, Cemiplimab, Computed Tomography - Leiomyosarcoma, Sarcoma | Phase 2 | Recruiting | Gabriel Tinoco | 16 | 2025-09-10 | 2026-10-01 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| Evaluation of Tretinoin Cream on the Integrity of Aged Forearm Skin Tretinoin 0.1% cream, Bland cream (non-drug) - Skin Tear, Solar Purpura | Phase 2 / Phase 3 | Completed | James Thomas Pathoulas | 15 | 2025-07-14 | 2026-05-28 |
| Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia Venetoclax, All-trans retinoic acid, Arsenic Trioxide (ATO) - Acute Promyelocytic Leukemia (APL) | Not applicable | Active not recruiting | Anhui Medical University | 28 | 2025-07-01 | 2025-09-23 |
| Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma Vesanoid, Standard radiotherapy, Tailored radiotherapy - Oropharynx Cancer, Larynx Cancer | Phase 3 | Recruiting | Centre Leon Berard | 460 | 2025-02-20 | 2026-04-24 |
| Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors Topical Tretinoin, Placebo - Metastatic Solid Tumor, Locally Advanced Solid Tumor | Phase 2 | Recruiting | University of Utah | 25 | 2025-02-19 | 2026-02-13 |
| Reverse HER2-negative Immune Resistant Breast Cancer Retinoic Acid, anti-PD-1 antibody and chemotherapy - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 10 | 2025-02-12 | 2025-11-17 |
| Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi Metformin gel, 30%, Triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%), Broad-spectrum sunscreen (SPF ≥30) - Melasma | Not applicable | Completed | Jinnah Postgraduate Medical Centre | 34 | 2025-02-01 | 2026-01-21 |
| ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT All-trans retinoic acid, zanubrutinib, radiotherapy - B-cell Non Hodgkin Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 35 | 2024-12-01 | 2024-11-01 |
| Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome tretinoin 0.025% + Z. officinale patch, tretinoin 0.025% cream - Acne Vulgaris | Phase 2 / Phase 3 | Active not recruiting | Hasanuddin University | 26 | 2024-11-03 | 2025-09-15 |
| ATRA and Carfilzomib in Plasma Cell Myeloma Patients All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose -1, All-Trans Retinoic Acid (ATRA) Dose 1 - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 42 | 2024-07-29 | 2026-04-03 |
Showing 20 of 190. Sign in to see all of them.
Acne Vulgaris (29) · Leukemia, Myeloid, Acute (27) · Leukemia, Promyelocytic, Acute (27) · Leukemia (16) · Myelodysplastic Syndromes (16) · Multiple Myeloma (9) · Melanosis (8) · Purpura, Thrombocytopenic, Idiopathic (8) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Melanoma (5) · Neuroblastoma (5) · Congenital Abnormalities (4) · Hematologic Neoplasms (4) · Leukemia, Erythroblastic, Acute (4)
Peking University People's Hospital (10) · Bausch Health Americas, Inc. (5) · M.D. Anderson Cancer Center (5) · Sun Pharmaceutical Industries, Inc. (5) · Memorial Sloan Kettering Cancer Center (4) · Children's Oncology Group (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Jinnah Postgraduate Medical Centre (3) · Johns Hopkins University (3) · National Cancer Institute (NCI) (3) · Spear Pharmaceuticals (3) · University of Ulm (3) · Associazione Italiana Ematologia Oncologia Pediatrica (2) · Coria Laboratories, Ltd. (2)
United States (89) · China (29) · Germany (15) · Italy (11) · France (9) · Canada (7) · Netherlands (7) · United Kingdom (6) · Australia (5) · Austria (4) · Belgium (4) · Spain (4) · Brazil (3) · Indonesia (3) · Israel (3)
Xiaohui Zhang, MD (3) · Alan K. Burnett, MD, FRCP (2) · Ana Rossi, MD (2) · David Lineberry (2) · Hemant Kocher, Professor (2) · Huaiyu Wang, Dr. (2) · Joseph G. Jurcic, MD (2) · Martin McCarter, MD (2) · Natalie Yantovskiy (2) · Oystein Bruserud, MD (2) · Raghu Nandan, MD (2) · Richard F Schlenk, Dr. (2) · Ronald W Gottschalk, MD (2) · Steven D. Gore, MD (2)
PMID 20684151, PMID 23841729, PMID 28877686, PMID 33917201, PMID 10438706, PMID 11904735, PMID 12243706, PMID 15337804, PMID 16247244, PMID 16484584, PMID 16826357, PMID 16982775, PMID 17315155, PMID 17596541, PMID 18532922, PMID 18922099, PMID 19007987, PMID 19059939, PMID 19124815, PMID 19153339, PMID 19291085, PMID 19602710, PMID 20018913, PMID 20038732, PMID 20644121, PMID 20705755, PMID 21343560, PMID 21385856, PMID 21751984, PMID 22395584, PMID 22712470, PMID 22829110, PMID 23863898, PMID 24127444, PMID 24488798, PMID 24528179, PMID 24746304, PMID 24797300, PMID 25184917, PMID 25245446, PMID 25270908, PMID 25396122, PMID 25470713, PMID 25975191, PMID 26008690, PMID 26308596, PMID 26700705, PMID 26864107, PMID 27400939, PMID 27465021
2015 (2), 2017 (2), 2019 (2), 2023 (2), 2025 (2), P30CA006973 (2), U10CA032102 (2), U10CA180886 (2), P01DK058335 (1), P30CA008748 (1), P30CA046592 (1), P30CA076292 (1), R01CA067803 (1), U10CA031946 (1), U10CA098543 (1)